Ying Yuan
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (51)
Supplementary Figure 9. Difference in baseline maximum VAF for detected somatic alterations. Panel (a) shows the maximum VAF according to the response category in patients with evaluable disease in the overall cohort. Panel (b) shows further stratification according to the treatment subprotocol.
Year:
2025
Purpose: Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in advanced/metastatic cancers. In this study, we report the correlation between ctDNA analysis of plasma samples collected from patients enrolled in the NCI-MATCH trial and tumor tissue–based sequencing. Experimental Design: We analyzed plasma samples collected from patients enrolled on 16 subprotocols of NCI-MATCH who had plasma samples collected within 90 days before starting treatment. Concordance was defined as the detection of the same gene alteration leading to patient enrollment in NCI-MATCH in both tissue and plasma. Results: We included 300 patients who were enrolled in NCI-MATCH. Most patients (81%, n = 243) were enrolled based on central tissue testing and had contemporaneous tissue and plasma samples. The tissue alteration of interest was detected in the plasma of 81.1% ( n = 197) of patients. Lower rates of detection of the tissue alteration of interest were observed in samples from 57 patients who were enrolled based on outside designated laboratory testing (56.1%, n = 32) and had noncontemporaneous tissue and plasma samples. Variations in concordance rates were observed with different alteration types, by maximum plasma variant allele frequency, and based on tumor biopsy site. Conclusions: The tumor tissue alteration of interest was detected in the plasma of 81% of patients who were enrolled in the NCI-MATCH trial based on central tissue testing and had contemporaneous tissue and plasma samples. This suggests a potential role for liquid biopsy in patient enrollment in trials evaluating biomarker-driven anticancer therapies. See related commentary by Russo et al., p. 4217
Year:
2025
Supplementary Table 9. Distribution of different genetic alterations according to response groups in different treatment arms. Shown in the table is the number of patients with molecular alteration in each response category.
Year:
2025
Supplementary Figure 8. Genomic alterations detected in patients treated in subprotocol Z1A enrolling patients with NRAS mutations who received treatment with binimetinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 5. Genomic alterations detected in patients treated in subprotocol Q enrolling patients with HER2 amplifications who received treatment with ado-trastuzumab emtansine. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 6. Genomic alterations detected in patients treated in subprotocol S1 enrolling patients with NF1 mutations who received treatment with trametinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 2. Summary of genomic landscape in patients enrolled based on outside laboratory testing who had discordant mutations. Patients are stratified according to the site of tissue biopsy (primary or metastatic site). Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 7. Genetic alterations detected in patients treated in subprotocol W enrolling patients with FGFR pathway alterations who received treatment with AZD4547. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 4. Genomic alterations detected in patients treated in subprotocol I enrolling patients with PIK3CA mutations who received treatment with taselisib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Supplementary Figure 3. Genomic alterations detected in patients treated in subprotocol G enrolling patients with ROS1 translocations who received treatment with crizotinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (43)
Janos Roszik
The University of Texas MD Anderson Cancer Center
Richard Yang
Assistant Professor, Molecular Genetic Pathology
The University of Texas MD Anderson Cancer Center
Alice Chen
Head, Early Clinical Trial Development Program
National Cancer Institute
Jianjun Gao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Joseph Abi Jaoude
Stanford Health Care
Aung Naing
The University of Texas MD Anderson Cancer Center
Roni Wilke
The University of Texas MD Anderson Cancer Center
Anil Sood
Professor
The University of Texas MD Anderson Cancer Center
Vivek Subbiah
Professor of Medicine and of Pediatrics
Stanford University
Apostolia M. Tsimberidou
Professor
The University of Texas MD Anderson Cancer Center
Sanghoon Lee
Associate Professor
The University of Texas MD Anderson Cancer Center
Amir Jazaeri
Professor
The University of Texas MD Anderson Cancer Center
David Gershenson
Professor
The University of Texas MD Anderson Cancer Center
Ruitao Lin
Associate Professor
The University of Texas MD Anderson Cancer Center
Jeffrey How
Assistant Professor
The University of Texas MD Anderson Cancer Center
Patricia LoRusso
Yale University
Elizabeth Euscher
Professor
MD Anderson Cancer Center
Yibo Dai
The University of Texas MD Anderson Cancer Center
Sarina Piha-Paul
Professor
The University of Texas MD Anderson Cancer Center
Shannon Westin
The University of Texas MD Anderson Cancer Center
Ramez Kouzy
The University of Texas MD Anderson Cancer Center
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Siqing Fu
Professor
The University of Texas MD Anderson Cancer Center
Yu Shyr
Professor and Chair
Vanderbilt University Medical Center
Gwyn Richardson
Professor
The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Ethan Ludmir
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
Ryan Sun
Assistant Professor
The University of Texas MD Anderson Cancer Center
Manoj Chelvanambi
The University of Texas MD Anderson Cancer Center
Pamela Soliman
Associate Professor
The University of Texas MD Anderson Cancer Center
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
R. Tyler Hillman
Associate Professor
UC San Diego Health System
Carlos L. Arteaga
University of Texas Southwestern Medical Center
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Kai Wucherpfennig
Professor and Department Chair
Dana-Farber Cancer Institute
Mohamed Gouda
The University of Texas MD Anderson Cancer Center
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Shubham Pant
Professor
The University of Texas MD Anderson Cancer Center
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
David Boruta
Professor
The University of Texas MD Anderson Cancer Center
Clifton D Fuller
Professor (Tenured)
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.